Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nanoviricides Inc (NY: NNVC ) 1.740 UNCHANGED Streaming Delayed Price Updated: 8:00 PM EDT, Sep 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Nanoviricides Inc < Previous 1 2 3 Next > MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX August 26, 2024 Via ACCESSWIRE NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections August 19, 2024 Via ACCESSWIRE NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics August 08, 2024 Via ACCESSWIRE Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market August 06, 2024 EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END Via FinancialNewsMedia Exposures COVID-19 Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect June 11, 2024 Via ACCESSWIRE The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect June 04, 2024 Via ACCESSWIRE Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses? August 02, 2024 Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 2, 2024) - Investorideas.com, a go-to investing platform covering biotech and... Via Newsfile Exposures COVID-19 "NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides August 01, 2024 Via ACCESSWIRE COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides July 24, 2024 Via ACCESSWIRE A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides July 11, 2024 Via ACCESSWIRE NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections July 01, 2024 Via ACCESSWIRE A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More May 29, 2024 Via ACCESSWIRE Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure May 20, 2024 Via ACCESSWIRE NanoViricides Has Filed its Quarterly Report May 15, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides June 24, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model June 20, 2024 Via ACCESSWIRE NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results May 29, 2024 Via AB Newswire NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc. May 23, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral with Activity Against RSV May 14, 2024 Via ACCESSWIRE NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City May 10, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox May 08, 2024 Via ACCESSWIRE A Novel Broad-Spectrum Antiviral with Activity Against Influenza A May 06, 2024 Via ACCESSWIRE NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon April 30, 2024 Via ACCESSWIRE NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon February 15, 2024 Via ACCESSWIRE Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics February 01, 2024 Via ACCESSWIRE Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found January 29, 2024 Via ACCESSWIRE NanoViricides to Present at the Biotech Showcase in San Fransisco January 04, 2024 Via ACCESSWIRE The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides November 28, 2023 Via ACCESSWIRE NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications November 15, 2023 Via ACCESSWIRE Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development November 14, 2023 Via ACCESSWIRE < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.